Author

Sasagu Tomioka

Observed name: S. Tomioka

Institution: Sumitomo Dainippon Pharma (United States)

Observed institutions: University Health Network, University of Toronto, Sumitomo Dainippon Pharma (Japan), Sunovion (United States), Sumitomo Dainippon Pharma (United States)

ORCID: 0000-0001-6927-2096

Observed ORCID: 0000-0001-6927-2096

OpenAlex ID: A5027088360

Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy

2009 · V. Bril, S. Tomioka, et al. · Diabetic Medicine · 243

Ranirestat for the Management of Diabetic Sensorimotor Polyneuropathy

2009 · Vera Bril, Toshiyuki Hirose, et al. · Diabetes Care · 109

Seizure monitoring by combined diary and wearable data: A multicenter, longitudinal, observational study

2025 · Solveig Vieluf, Sasagu Tomioka, et al. · Epilepsia · 9

Evaluating speech latencies during structured psychiatric interviews as an automated objective measure of psychomotor slowing

2024 · Alex S. Cohen, Zachary Rodriguez, et al. · Psychiatry Research · 8

Assessment of Negative Symptoms in Clinical Trials of Acute Schizophrenia: Test of a Novel Enrichment Strategy

2022 · Seth C Hopkins, Sasagu Tomioka, et al. · Schizophrenia Bulletin Open · 8

Enrichment using speech latencies improves treatment effect size in a clinical trial of bipolar depression

2024 · Joshua S. Siegel, Alex S. Cohen, et al. · Psychiatry Research · 6

Estimating heterogeneity of treatment effect in psychiatric clinical trials

2025 · Joshua S. Siegel, Jinglin Zhong, et al. · Journal of Psychiatric Research · 2

A clinical trial inclusion criteria to enrich for patients presenting with canonical symptom structure in bipolar depression

2024 · Seth C. Hopkins, Sasagu Tomioka, et al. · Contemporary Clinical Trials · 2

Works count: 8

Citation count: 387

H-index: 6

I10-index: 2